Chicago-based private equity group First Analysis expects its $12 million cash infusion into Sonoma Orthopedic Products will be sufficient for the startup to gain FDA clearance for a new ankle implant--as well as to launch it and start to scale up sales.
After recent courtroom losses for Johnson & Johnson and Boston Scientific in cases involving vaginal mesh implants, a federal judge encouraged C.R. Bard to settle the thousands of similar lawsuits it faces. In doing so, he cited the responsibility of the company to its shareholders to limit losses, according to a Bloomberg article.
St. Jude Medical has gained approval for a quadripolar cardiac resynchronization therapy pacemaker that for the first time incorporates its MultiPoint Pacing technology that's been shown to be better for patients who don't respond to traditional biventrical pacing.
SetPoint Medical is starting a clinical trial to treat Crohn's disease patients with its implantable neuromodulation device. The startup previously reported a positive pilot study of the device to treat rheumatoid arthritis.
Pixium Vision, which had its IPO in June, is ready to head to European regulators with a retinal implant.
Conventus Orthopaedics received $24 million in its first equity financing that will go to launch its distal radius fracture implant as well as to advance other minimally invasive complex fracture treatments.
Physicians can add another tool to their arsenal that targets chronic back pain locally, without requiring surgery or an external device. The FDA has cleared Stimwave's Freedom Spinal Cord Stimulation System, which the company says is the smallest available neuromodulation device.
Dialysis provider DaVita HealthCare Partners has partnered with Medtronic for a pilot program to study cardiac arrhythmias in end-stage renal disease patients receiving dialysis. It will use the tiny implantable cardiac monitor, Linq, which Medtronic launched early this year.
Cardiovascular device company Sorin Group has invested $20 million in Respicardia. The financing is to be used to fund ongoing clinical testing of the startup's remede System, which is a pacemaker-like device for central sleep apnea that delivers electrical pulses via an implantable lead to the phrenic nerve.
Stanford seems to have found a niche in tiny wireless implants. In the latest development, the university announced that it is developing methods of beaming ultrasound to power implanted "smart chips" for the treatment of conditions like Parkinson's disease.